Dr. Michael Byrne is CEO of Satisfai Health and founder of ai4gi, and provides senior leadership and clinical direction to Satisfai, and to the ai4gi joint venture. In 2018, a co-development agreement was entered between Olympus America and the ai4gi joint venture to explore AI opportunities in colon polyp disease.
Dr Byrne is widely regarded as one of the leading physician experts in Artificial Intelligence as applied to Gastroenterology. He is a clinical innovator and physician entrepreneur with more than twenty years experience as a practicing physician.
Specializing in gastroenterology and interventional endoscopy, Dr. Byrne is currently a Clinical Professor of Medicine in the Division of Gastroenterology, and was the Director of Endoscopy at Vancouver General Hospital/University of British Columbia from 2012-2014. He is the current Director of the Interventional Endoscopy Fellowship programme at Vancouver General Hospital/University of British Columbia. Dr. Byrne is a graduate of Cambridge University, and trained in advanced endoscopy at Duke University.
His research interests range from basic science to clinical medicine, and he has hands-on research training in molecular science and pharmacology. His clinical experience and research interests include many aspects of interventional endoscopy and general gastroenterology and the overlaps with oncology and diagnostic imaging. Dr. Byrne was previously the co-director of the Luminal Clinical Trials Group at VGH/UBC and has been the principal investigator or co-investigator in numerous clinical trials.
He has published over 100 papers in peer-reviewed journals, over 200 abstracts, and presented at many international conferences, particularly in relation to Artificial Intelligence and Gastroenterology in the last few years.